Hi @mansur_TL

idea for the future for Colibri-sm 🙏

"Super Follows" is a way for people’s most engaged followers to help them earn money for their contributions on Twitter. When someone offers a Super Follows subscription, their Super Followers can see bonus Tweets created especially for them. Super Followers receive badges on all their replies to the person they’ve Super Followed, letting them stand out in the conversation.

https://twitter.com/SuperF...

About -us

https://help.twitter.com/e...

#superfollows #ideas #colibrism #Teskale

AT PRESENT, MORE THAN 100 COMPANIES ACROSS THE GLOBE CLAIM INTERPRETATION OF DIFFERENT TYPES OF MEDICAL IMAGES
During our research, we came across 105 service providers that are presently engaged in providing teleradiology services. The domain is currently dominated by small (40%) and mid-sized players (33%). This can be attributed to the fact that healthcare domain has seen a shift from traditional image interpretation services to teleradiology services in the recent years, especially with increase in cases where the patients are not able to frequently visit their healthcare professional due to the lockdowns imposed because of COVID-19 pandemic. Further, increased preference of radiologists to work from home, due to COVID-19, has spurred the establishment of many start-ups in this domain.

To request for Sample report - https://www.rootsanalysis....

Even though teleradiology services are being provided by players based all across the globe, most of the service providers engaged in this domain (~40%) are headquartered in North America, followed by Asia, Europe, Middle East and North Africa, and South America.

During our research, we observed that majority (81%) of the teleradiology service providers offer teleradiology services for both CT scan and MRI image interpretations. This is followed by players offering X-ray (67%), ultrasound (60%), and PET (41%). Examples of the companies processing all types of images include (in alphabetical order with no selection criteria) 4ways Healthcare, XXX, XXX, XXX, and Cloudex Radiology.
To request for customize report - https://www.rootsanalysis....

Currently, majority (18%) of the service providers are offering teleradiology solutions for interpretation of mammography specific images, followed by musculoskeletal (17%), neuroradiology (16%), nuclear medicine (15.5%), cardiology (14%), pediatrics (12.5%), and oncoradiology (25). Some of the players that offer teleradiology solutions for interpretation of all types of subspecialty images include (in alphabetical order, with no selection criteria), XXX, All-American Teleradiology, XXX, XXX, and Narayana Health.

Majority (84%) of the teleradiology service providers are offering services to hospitals, followed by diagnostic / imaging centers (45%), and patients (11%). Some of the players that offer teleradiology services to all types of end users include (in alphabetical order) include, BalticRAD, XXX, and National Diagnostic Imaging.

For more information please click on the following link: - https://www.rootsanalysis....

Other Recent Offerings
1. TIL-based Therapies Market, 2021-2030
2. TCR-based Therapies Market, 2021-2030
3. Peptide Therapeutics Market, 2021-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

IN ORDER TO COPE UP WITH THE CURRENT AND FUTURE MARKET DEMAND

In the pharmaceutical industry, stakeholders are known to adopt a variety partnership models. Such initiatives not only allow the companies to expand their respective product / therapy, but also to gain additional capabilities in emerging technologies. In the domain of TIL-based therapies, eleven different types of partnership deals were found to be inked between different stakeholders. These include, acquisition, clinical trial agreement, joint venture, manufacturing agreement, product development agreement, product development and commercialization agreement, product licensing agreement, product supply management agreement, R&D agreement, technology licensing and others.

During our research, we came across several partnership agreements, inked during the period 2005-2020 (till October). The number of partnerships has increased at a CAGR of 53%, between 2014 and 2020. It is important to highlight that maximum number of partnerships were recorded in 2017, 2018 and 2019, followed by 2015 (6). Majority of the deals signed in 2016, were R&D agreements, followed by agreements signed for technology licensing, clinical trial agreements and manufacturing agreements.

Majority (33%) of the agreements were signed for R&D (13) and technology and product licensing (8) of TIL-based products. This is followed by agreements focused on manufacturing (15%), clinical trials and product supply management, which account for 5% each of the total partnerships inked in this domain, respectively. Recent examples include the product licensing agreement signed between Iovance Biotherapeutics and TrakCel in September 2017.[1]
To request for Sample report - https://www.rootsanalysis....
Funding Initiatives

The technological advancements in this domain, and the promising results of preclinical / clinical studies of various product candidates have garnered the attention of several investors. Given the innate advantages offered by immunotherapeutics, this emerging market has done exceedingly well in terms of raising funds. The strong and steady performance, in terms of research-related advances and flow of finances, has been favorable to this market. Investments from venture capital investors have helped start-ups, such as Iovance Biotherapeutics and Cellular Biomedicine Group, to become the current leaders in the TIL-based therapies market.

To request for customize report - https://www.rootsanalysis....

Given the current trend, it can be stated that investment from venture funding rounds is a key enabler for growth in the TIL-based therapies market. Companies in this domain have raised significant capital through venture rounds (30%), amounting to USD 68 billion. Some big-ticket investments include (in decreasing order of amount) Iovance Biotherapeutics (USD 170 million) and Cellular Biomedicine Group (USD 10 million). This is followed by secondary offerings, which account for 24% of the total number of instances, amounting to USD 1.1 billion. Further, we came across 4 instances of venture capital investments received by companies from various industrial and non-industrial organizations. Examples of the players that have received venture capital investments include (in decreasing order of amount) Achilles Therapeutics, Instil Bio, PACT Pharma, Intrexon, KSQ Therapeutics and Phio Pharmaceuticals.
For additional details, please visit - https://www.rootsanalysis....

You may also be interested in the following titles:
1. TIL-based Therapies Market, 2021-2030
2. TCR-based Therapies Market, 2021-2030
3. Peptide Therapeutics Market, 2021-2030

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

TOP SELLING BIOLOGICS MARKET - GAINING TRACTION IN THE PHARMACEUTICAL INDUSTRY
Less than half a century ago, the pharmaceutical market was dominated by small molecule drugs. However, owing to concerns, such as off target toxicity and low specificity, associated with chemical moieties, and the need to shift from the one-size-fits-all approach to personalized medicine, a better class of pharmacological interventions was required. The first biologic drug, humanized insulin, was approved in 1982; over time, this class of target specific therapeutics have revolutionized the healthcare industry. Briefly, biologics offer several benefits, including target specificity, better therapeutic efficacy and, consequently, favorable safety profiles compared to conventional chemical-based drugs. Moreover, these molecules have also demonstrated the ability to access elusive biological targets and treat diseases that were previously considered undruggable.
To request for Sample report - https://www.rootsanalysis....

Presently, biologics represent the fastest growing product segment within the global pharmaceutical industry. In fact, as of September 2020, over 430 biological interventions were approved for the treatment of various disease indications in the US and Europe. Given the advantages they offer, biologics are in high demand for the treatment of different disease indications. It is a well-known fact that antibodies emerged as the major therapeutic breakthroughs and have seen significant success in the past two decades. There are other vast opportunities for biologics in the foreseeable future. This segment of healthcare industry is in the midst of numerous innovations; examples include antibody drug conjugates, immunotherapies, bispecific antibodies, combination therapeutics, and gene and cell therapies. These developments have set the stage for significant disruption, creating more therapeutic targets and, ultimately, taking personalized healthcare to new and astounding heights. Since 2015, six orally administrable drugs, manufactured using the continuous technique, have been approved by the FDA; these are TRIKAFTA® (Vertex Pharmaceuticals, 2019), DAURISMO™ (Pfizer, 2018), SYMDEKO® (Vertex Pharmaceuticals, 2018), VERZENIO® (Eli Lilly, 2017), PREZISTA® (Johnson & Johnson, 2016) and ORKAMBI® (Vertex Pharmaceuticals, 2015).[1], [2],[3], [4]
To request for customize report - https://www.rootsanalysis....

Based on the active substances used, therapeutics can be categorized into two main segments, namely small molecules and biologics, that are currently available / being developed by players engaged in the pharmaceutical industry.

Since biologics are essentially structural analogues of various biomolecules found in the human body, they have highly specific mechanisms of action and fewer side effects, as compared to the conventional pharmacological molecules (mostly small molecules).

As a result, biologics are thought to possess the potential to target and eradicate the root cause of diseases at a cellular / genetic level.

For additional details, please visit - https://www.rootsanalysis....

You may also be interested in the following titles:
1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

DESPITE OF AN EXHAUSTIVE MECHANISM OF DNA PROCESSING AND ITS HIGHLY STABLE STRUCTURE, DNA IS BOUND TO UNDERGO DAMAGE BY SEVERAL FACTORS
DNA damage can be referred to as any adverse alteration, which may occur in the form of base additions, base deletions or break in the sister DNA strands. Damage of genetic material is known to interfere with essential cellular processes, such as transcription and DNA replication. DNA lesions at specific positions have been shown to be associated with the induction of heritable mutations. The accumulation of such erroneous elements in the genetic code may ultimately result in cellular aberrations, compromising structure, function, and viability. Such adverse alterations may also form the genetic basis of a variety of diseases. In fact, chromosomal aberrations and germline mutations often lead to the loss of function of tumor suppressor genes and / or those coding for essential cell cycle checkpoint proteins, which may result in uncontrollable cellular proliferation and thereby, the development of disease indications, such as cancer.
To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis....

Researchers have estimated the total number of DNA damaging events per cell, per day, to be around 60,000. Further extrapolations suggest that there are about 3×1017 DNA damaging events taking place, per hour, in the human body. However, in eukaryotes, the likely adverse events / health implications associated with DNA damage are largely prevented by a robust DNA repair system.

DNA damage can be caused by a series of chemical events, such as hydrolysis, interactions with reactive oxygen species and other reactive metabolites, which are consequences of exposure to both exogenous and endogenous factors. In higher eukaryotes, various DNA repair mechanism are involved in the repair of the specific damage caused by both, exogenous and endogenous factors. Further, they also possess an elaborate and highly coordinated DNA damage response (DDR) system. This system is responsible for identifying damaged DNA segments, tagging DNA lesions and signaling their presence in the genome, and in turn mediating a corrective response, which usually results in either the development of tolerance or DNA repair. The response system is comprised of a family of molecular entities (including sensors, transducers and effectors) that facilitate and / or mediate the repair process. Common responses to DDR signaling include activation of transcription, cell cycle control, DNA repair pathways, apoptosis, senescence and cell death. The various DNA damage tolerance and repair mechanisms in eukaryotes have been briefly described below:
To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

 DNA Damage Tolerance: Despite the presence of several repair mechanisms, it is likely that certain errors that are improperly repaired or entirely unrepaired, may interfere with the DNA replication process. This results in the collapse of the replication fork, further leading to genomic instability. In such cases, the DNA damage tolerance pathway gets activated, and recruits a specialized low fidelity translesion synthesis polymerase capable of bypassing lesions and leaving them for repair at a later time point. This pathway restarts the halted replication fork, and is therefore, integral to the completion of the replication process, despite the presence of lesions in DNA. Once the replication process is completed, all the remaining lesions are tagged and subjected to repair. This process is primarily convened by two specialized pathways, namely the translesion synthesis (TLS) and template switching (TS) pathways.

 DNA Damage Repair (DDR): This system involves a coordinated sequence of events, involving the detection of DNA damage points (by sensor proteins), followed by the transduction of information ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) and the subsequent repair of damaged DNA segments.

For more information please click on the following link: - https://www.rootsanalysis....

Other Recent Offerings
1. TIL-based Therapies Market, 2021-2030
2. TCR-based Therapies Market, 2021-2030
3. Peptide Therapeutics Market, 2021-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

DIGITAL THERAPEUTICS – INCREASING REGULATORY SUPPORT HAS AIDED IN ESTABLISHING A STANDARD DEVELOPMENTAL PATHWAY FOR THESE SOLUTIONS
Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing motivational support and inculcating healthy lifestyle changes.
To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis....

Several organizations have undertaken diverse initiatives in the field of digital therapeutics to support its growth as a new frontier in the healthcare sector. A number of organizations focused on effectively monitoring and promoting the potential of digital therapeutics to be used as a part of strategies to improve the population health have also been established. These organizations include:
 Digital Therapeutics Alliance (DTA)
 Personal Connected Health (PCH) Alliance
 Centers for Disease Control and Prevention (CDC)
 Health Insurance Portability and Accountability Act (HIPAA)
 National Health Service (NHS)
 United States Food and Drug Administration (USFDA)

Traversing a digital therapeutic from the R&D stage to the market is a long process. The various developmental stages involved in this process have been discussed in detail in the following sections.
 Discovery and Preclinical Phase: The discovery phase involves the identification of a novel digital therapeutic intervention. At this stage, researchers publish their work in academic journals and continue to investigate the potential applications of their digital solutions in disease treatment / management.

 Clinical Trials and Validation: This phase involves the conduct of proper clinical trials to validate the claims made by a digital therapeutic solution providers, and to evaluate its potential in a real-world setting. It includes testing of the software / hardware on a specific patient population. In case of clinical studies, health outcomes are measured and tracked through data driven insights provided by the software. Disease specific improvements (post application / implementation of the intervention) are also tracked to evaluate the performance of a product. There are multiple challenges associated with conducting clinical trials for digital therapeutics. Firstly, technologies are known to change rapidly and there is a very high probability for a software to undergo upgrades / improvements over the duration of a clinical trial. As a result, there are technical issues in storing and updating patient data. Secondly, digital interventions cannot be studied in a double-blind manner, because the investigator is always aware of whether a trial subject is in the control group or being treated with the intervention under evaluation. Finally, at present, there is less structure and guidelines available, and as a result meaningful and conclusive insights are difficult to be drawn from such trials.

 Negotiations with Insurance Providers / Payers: Post the successful completion of clinical studies, developer companies generally tend to avail reimbursement opportunities for their products in order to promote the use of their proprietary solutions and provide financial benefits to patients / consumers. As is the case with pharmacological interventions, reimbursement plans for these products can be achieved based on the outcomes of clinical trials and depending on the USFDA’s (or the concerned regulatory authority of a particular region) clearance. A number of health insurance providers, such as Medicare and Humana, are actively working to include digital therapeutics as a part of health insurance coverage plans for patients suffering from chronic diseases.

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

 Distribution and Marketing: The pharmaceutical and medical device distribution / marketing system is an established network with well-defined channels through which manufacturers can reach the end-users of their products. Product developers in this domain are presently looking to create a distribution network to sell their offerings in the market via both B2B (healthcare providers, regulators and payers) and B2C (customer) models.

For additional details, please visit - https://www.rootsanalysis....

You may also be interested in the following titles:
1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

PRESENTLY, OVER 40 PLAYERS, BASED IN DIFFERENT REGIONS OF THE WORLD CLAIM TO OFFER BIOASSAY SERVICES FOR CELL

During our research, we were able to capture more than 40 players, which claims to offer bioassay services related for cell and gene therapies.
Report Link -https://www.rootsanalysis....

Amongst the total players offering bioassay services for cell and gene therapies, most of the players engaged in this domain were established before 1995. Of these, nine are headquartered in North America, while eight are based in Europe. Further, the industry witnessed the establishment of nine players, post 2010. Of these, five are based in North America, three in Europe and one in the Asia-Pacific region. In addition to this, all of the bioassay service providers (100%) are offering pre-developed assay. This is followed by 89% players that offer customized assays for cell and gene therapies.

For Customize report -https://www.rootsanalysis....

Further, as can be observed from the figure, 75% service providers claim to have the required capabilities to offer services related to immunoassay. Besides this, we came across two companies which offer all the aforementioned bioanalytical services. Examples of such players include (in alphabetical order), BioAgilytix and PPD Laboratories. It is worth highlighting that, of the total companies offering bioassay services, close to 60% offer services both in vitro as well as in vivo type of bioassay for cell and gene therapies.

As the figure represents, majority are mid-sized players (48%). Of these, most (25%) of companies have been established between 2000 to 2010. This is followed by the large firms (36%), of which companies established before 1945 are (in reverse chronological order of year of establishment) BD Biosciences (1897), Lonza (1897), SGS (1878), Siemens Healthineers (1847) and Merck KGaA (1668).

For free Insights - https://www.rootsanalysis....

Majority of the companies (89%) offer bioassay services for cell therapies, followed by 86% companies offering bioassay services for gene therapies. Further, immunoassay was found to be the most common bioanalytical service, provided by 75% companies. This is followed by potency assay and ELISA offered by 66% bioassay service providers.

For additional details, please visit – https://www.rootsanalysis....

You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
2. CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

DESPITE OF AN EXHAUSTIVE MECHANISM OF DNA PROCESSING AND ITS HIGHLY STABLE STRUCTURE, DNA IS BOUND TO UNDERGO DAMAGE BY SEVERAL FACTORS
DNA damage can be referred to as any adverse alteration, which may occur in the form of base additions, base deletions or break in the sister DNA strands. Damage of genetic material is known to interfere with essential cellular processes, such as transcription and DNA replication. DNA lesions at specific positions have been shown to be associated with the induction of heritable mutations. The accumulation of such erroneous elements in the genetic code may ultimately result in cellular aberrations, compromising structure, function, and viability. Such adverse alterations may also form the genetic basis of a variety of diseases. In fact, chromosomal aberrations and germline mutations often lead to the loss of function of tumor suppressor genes and / or those coding for essential cell cycle checkpoint proteins, which may result in uncontrollable cellular proliferation and thereby, the development of disease indications, such as cancer.

To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis....

Researchers have estimated the total number of DNA damaging events per cell, per day, to be around 60,000. Further extrapolations suggest that there are about 3×1017 DNA damaging events taking place, per hour, in the human body. However, in eukaryotes, the likely adverse events / health implications associated with DNA damage are largely prevented by a robust DNA repair system.

DNA damage can be caused by a series of chemical events, such as hydrolysis, interactions with reactive oxygen species and other reactive metabolites, which are consequences of exposure to both exogenous and endogenous factors. In higher eukaryotes, various DNA repair mechanism are involved in the repair of the specific damage caused by both, exogenous and endogenous factors. Further, they also possess an elaborate and highly coordinated DNA damage response (DDR) system. This system is responsible for identifying damaged DNA segments, tagging DNA lesions and signaling their presence in the genome, and in turn mediating a corrective response, which usually results in either the development of tolerance or DNA repair. The response system is comprised of a family of molecular entities (including sensors, transducers and effectors) that facilitate and / or mediate the repair process. Common responses to DDR signaling include activation of transcription, cell cycle control, DNA repair pathways, apoptosis, senescence and cell death. The various DNA damage tolerance and repair mechanisms in eukaryotes have been briefly described below:

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

DNA Damage Tolerance: Despite the presence of several repair mechanisms, it is likely that certain errors that are improperly repaired or entirely unrepaired, may interfere with the DNA replication process. This results in the collapse of the replication fork, further leading to genomic instability. In such cases, the DNA damage tolerance pathway gets activated, and recruits a specialized low fidelity translesion synthesis polymerase capable of bypassing lesions and leaving them for repair at a later time point. This pathway restarts the halted replication fork, and is therefore, integral to the completion of the replication process, despite the presence of lesions in DNA. Once the replication process is completed, all the remaining lesions are tagged and subjected to repair. This process is primarily convened by two specialized pathways, namely the translesion synthesis (TLS) and template switching (TS) pathways.

DNA Damage Repair (DDR): This system involves a coordinated sequence of events, involving the detection of DNA damage points (by sensor proteins), followed by the transduction of information ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) and the subsequent repair of damaged DNA segments.

For more information please click on the following link: - https://www.rootsanalysis....

Other Recent Offerings

TIL-based Therapies Market, 2021-2030
TCR-based Therapies Market, 2021-2030
Peptide Therapeutics Market, 2021-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnsonrootsanalysis.com

Roots Analysis

Web: https://www.rootsanalysis....

LinkedIn: https://in.linkedin.com/co...

Twitter: https://twitter.com/RootsA...

Medium: https://medium.com/RootsA...

Pinterest: https://in.pinterest.com/R...

Quora: https://rootsanalysisinsig...

IN PURSUIT OF A COMPETITIVE EDGE, STAKEHOLDERS ARE ACTIVELY EXPANDING THEIR EXISTING CAPABILITIES TO ENHANCE

The primary purpose of this analysis was to develop a deeper understanding of the overall strength of the contract service providers involved in this field. It allows companies to compare their existing capabilities within their respective peer groups and identify ways to gain a competitive edge in the industry. In addition, this analysis can be used by the companies to ascertain improvement areas by identifying the gaps between their existing capabilities and the best available practices in the industry.

For Customize report -https://www.rootsanalysis....

In this analysis, we have compared more than 40 bioassay service providers offering services for cell and gene therapies across multiple parameters. We have analyzed all the companies and plotted a four-dimensional bubble analysis with supplier strength on the abscissa, service strength on the ordinate and service applicability as the size of the bubble. The primary purpose of this analysis is to compare the popularity and activity of different cell and gene therapy bioassay service providers on a relative basis. At no point, should the discussion in this analysis be construed as a firm recommendation that one service provider is better than the others. It is important to mention that this analysis has been done based on the information collated from various publicly available sources and the information disclosed by the company.

As it can be seen in the above figure, Company 4, a large company emerged as the leading player in terms of service strength. The company offers bioassay services for both cell and gene therapies via different facilities. The facilities from which company offers its bioanalytical services, include US (Wisconsin, Virginia and Kentucky), China (Shanghai and Suzhou), Brussels, Belgium and Singapore. Further, the company has the capability to offer different types of bioanalytical services, including immunoassay, potency assay, flow chemistry, quantitative PCR, digital droplet PCR, immunochemistry, ELISA, mass spectroscopy, cell-based assays and molecular genomics.

For free Insights - https://www.rootsanalysis....

Further, it is worth mentioning that Company 1 has maximum score in terms of supplier strength. The company offers pre-developed bioassay services for both cell and gene therapies. In addition, the company offer immunoassays, potency assays and flow cytometry from its bioanalytical facility located in Europe.

For additional details, please visit – https://www.rootsanalysis....

You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
2. CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

DIGITAL THERAPEUTICS – INCREASING REGULATORY SUPPORT HAS AIDED IN ESTABLISHING A STANDARD DEVELOPMENTAL PATHWAY FOR THESE SOLUTIONS

Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing motivational support and inculcating healthy lifestyle changes.
To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis....

Several organizations have undertaken diverse initiatives in the field of digital therapeutics to support its growth as a new frontier in the healthcare sector. A number of organizations focused on effectively monitoring and promoting the potential of digital therapeutics to be used as a part of strategies to improve the population health have also been established. These organizations include:
 Digital Therapeutics Alliance (DTA)
 Personal Connected Health (PCH) Alliance
 Centers for Disease Control and Prevention (CDC)
 Health Insurance Portability and Accountability Act (HIPAA)
 National Health Service (NHS)
 United States Food and Drug Administration (USFDA)

Traversing a digital therapeutic from the R&D stage to the market is a long process. The various developmental stages involved in this process have been discussed in detail in the following sections.
 Discovery and Preclinical Phase: The discovery phase involves the identification of a novel digital therapeutic intervention. At this stage, researchers publish their work in academic journals and continue to investigate the potential applications of their digital solutions in disease treatment / management.

 Clinical Trials and Validation: This phase involves the conduct of proper clinical trials to validate the claims made by a digital therapeutic solution providers, and to evaluate its potential in a real-world setting. It includes testing of the software / hardware on a specific patient population. In case of clinical studies, health outcomes are measured and tracked through data driven insights provided by the software. Disease specific improvements (post application / implementation of the intervention) are also tracked to evaluate the performance of a product. There are multiple challenges associated with conducting clinical trials for digital therapeutics. Firstly, technologies are known to change rapidly and there is a very high probability for a software to undergo upgrades / improvements over the duration of a clinical trial. As a result, there are technical issues in storing and updating patient data. Secondly, digital interventions cannot be studied in a double-blind manner, because the investigator is always aware of whether a trial subject is in the control group or being treated with the intervention under evaluation. Finally, at present, there is less structure and guidelines available, and as a result meaningful and conclusive insights are difficult to be drawn from such trials.

 Negotiations with Insurance Providers / Payers: Post the successful completion of clinical studies, developer companies generally tend to avail reimbursement opportunities for their products in order to promote the use of their proprietary solutions and provide financial benefits to patients / consumers. As is the case with pharmacological interventions, reimbursement plans for these products can be achieved based on the outcomes of clinical trials and depending on the USFDA’s (or the concerned regulatory authority of a particular region) clearance. A number of health insurance providers, such as Medicare and Humana, are actively working to include digital therapeutics as a part of health insurance coverage plans for patients suffering from chronic diseases.

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

 Distribution and Marketing: The pharmaceutical and medical device distribution / marketing system is an established network with well-defined channels through which manufacturers can reach the end-users of their products. Product developers in this domain are presently looking to create a distribution network to sell their offerings in the market via both B2B (healthcare providers, regulators and payers) and B2C (customer) models.

For additional details, please visit - https://www.rootsanalysis....

You may also be interested in the following titles:
1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Polycystic Ovary Syndrome 2021-2031 by Roots Analysis

Owing to the complexities associated with the production of biologics, biopharmaceutical developers are likely to continue relying on contract service providers for various aspects of their respective product development programs
London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030” report to its list of offerings.
Given the rising popularity of biologics and the 8,000+ such product candidates under clinical investigation, the opportunity for contract manufacturing service providers engaged in this domain, is high and anticipated to persist in the mid-long term, as well. In fact, since 2000, over 120 new CMOs have been established, offering a variety of cost-efficient manufacturing services and solutions to biologic developers.
To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights
Presently, 225 CMOs, possessing over 380 manufacturing facilities, claim to offer manufacturing services for biopharmaceutical products
The manufacturing services market for biopharmaceuticals is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 60% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation.

More than 65% of service providers offer manufacturing services for recombinant proteins and peptides
Close to 58% of CMOs claim to have the required capabilities to offer antibody manufacturing services. It is worth mentioning that a number of biologics manufacturers are presently offering services related to the niche and emerging classes of biologics.

Over 620 partnerships were established in this domain, during the period 2015-2020
Majority of the deals (~24%) recorded in the report, were established in 2020, primarily driven by the investigational biologic drugs against COVID-19. Further, a large number (~35%) of the partnerships were observed to be focused on the manufacturing of biologics, followed by product development and manufacturing agreements (22%).

Currently, the installed biopharmaceutical contract manufacturing capacity is estimated to be ~3.9 million liters, which is gradually being expanded
In order to meet the growing demand for biologics, 177 expansion projects were undertaken by CMOs between 2016 and 2020 Of the aforementioned initiatives, more than 40% were focused on the establishment of new facilities, followed by the expansion of existing manufacturing facilities (24%).

North America and Europe are anticipated to capture 75% share (in terms of service revenues) of the market, by 2030
At present, close to 90% of the total revenues are generated from projects involving commercialized biologic products, and this trend is unlikely to change significantly in the short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (13.6%), followed by the Asia-Pacific market (11.2%).

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

The USD 34.2 billion (by 2030) financial opportunity within the biopharmaceutical contract manufacturing market has been analyzed across the following segments:
 Commonly outsourced business operations
 API
 FDF

 Types of Expression Systems Used
 Mammalian
 Microbial
 Others

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Types of Biologics Manufactured
 Antibody Therapeutics
 Vaccines
 Cell Therapies
 Other Biologics

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa

The report includes profiles of key players (listed below) each profile features an overview of the company, information related to its biologics focused service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
 AGC Biologics
 Boehringer Ingelheim
 Catalent
 Cytiva (GE Healthcare)
 FUJIFILM Diosynth Biotechnologies
 KBI Biopharma
 Kemwell Biopharma
 Lonza
 Luina Bio
 Novasep
 Olon
 Patheon
 Piramal Pharma Solutions
 Takara Bio
 WuXi AppTec (WuXi Biologics)

For additional details, please visit
https://www.rootsanalysis.... email salesrootsanalysis.com

You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
2. ADC Contract Manufacturing Market (4th Edition), 2020-2030
3. Microbial Contract Manufacturing Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030

Owing to the complexities associated with the production of biologics, biopharmaceutical developers are likely to continue relying on contract service providers for various aspects of their respective product development programs
London
Roots Analysis has announced the addition of the “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030” report to its list of offerings.
Given the rising popularity of biologics and the 8,000+ such product candidates under clinical investigation, the opportunity for contract manufacturing service providers engaged in this domain, is high and anticipated to persist in the mid-long term, as well. In fact, since 2000, over 120 new CMOs have been established, offering a variety of cost-efficient manufacturing services and solutions to biologic developers.
To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis....

Key Market Insights
Presently, 225 CMOs, possessing over 380 manufacturing facilities, claim to offer manufacturing services for biopharmaceutical products
The manufacturing services market for biopharmaceuticals is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 60% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation.

More than 65% of service providers offer manufacturing services for recombinant proteins and peptides
Close to 58% of CMOs claim to have the required capabilities to offer antibody manufacturing services. It is worth mentioning that a number of biologics manufacturers are presently offering services related to the niche and emerging classes of biologics.

Over 620 partnerships were established in this domain, during the period 2015-2020
Majority of the deals (~24%) recorded in the report, were established in 2020, primarily driven by the investigational biologic drugs against COVID-19. Further, a large number (~35%) of the partnerships were observed to be focused on the manufacturing of biologics, followed by product development and manufacturing agreements (22%).

Currently, the installed biopharmaceutical contract manufacturing capacity is estimated to be ~3.9 million liters, which is gradually being expanded
In order to meet the growing demand for biologics, 177 expansion projects were undertaken by CMOs between 2016 and 2020 Of the aforementioned initiatives, more than 40% were focused on the establishment of new facilities, followed by the expansion of existing manufacturing facilities (24%).

North America and Europe are anticipated to capture 75% share (in terms of service revenues) of the market, by 2030
At present, close to 90% of the total revenues are generated from projects involving commercialized biologic products, and this trend is unlikely to change significantly in the short to mid-term. Further, it is worth mentioning that the contract biomanufacturing market for biologics in the Middle East and North Africa is anticipated to grow at a relatively faster rate (13.6%), followed by the Asia-Pacific market (11.2%).

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

The USD 34.2 billion (by 2030) financial opportunity within the biopharmaceutical contract manufacturing market has been analyzed across the following segments:
 Commonly outsourced business operations
 API
 FDF

 Types of Expression Systems Used
 Mammalian
 Microbial
 Others

 Scale of Operation
 Preclinical / Clinical
 Commercial

 Company Size
 Small
 Mid-sized
 Large / Very Large

 Types of Biologics Manufactured
 Antibody Therapeutics
 Vaccines
 Cell Therapies
 Other Biologics

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa

The report includes profiles of key players (listed below) each profile features an overview of the company, information related to its biologics focused service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
 AGC Biologics
 Boehringer Ingelheim
 Catalent
 Cytiva (GE Healthcare)
 FUJIFILM Diosynth Biotechnologies
 KBI Biopharma
 Kemwell Biopharma
 Lonza
 Luina Bio
 Novasep
 Olon
 Patheon
 Piramal Pharma Solutions
 Takara Bio
 WuXi AppTec (WuXi Biologics)

For additional details, please visit
https://www.rootsanalysis.... email salesrootsanalysis.com

You may also be interested in the following titles:
1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
2. ADC Contract Manufacturing Market (4th Edition), 2020-2030
3. Microbial Contract Manufacturing Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Twitter gives you balloons on your profile for your birthday, it would be cool to see that added to #colibrism and I think you should add your join date ( cake day ) with balloons or special fireworks. #ideas

TIL-based Therapies Market by Roots Analysis
Driven by the potential to confer sustained therapeutic effects and thereby facilitate prolonged periods of remission, TIL-based therapies have received significant financial support, and promising leads are poised to soon achieve blockbuster status

Roots Analysis has announced the addition of “TIL-based Therapies Market, 2021-2030” report to its list of offerings.

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
 A detailed assessment of the current market landscape of drug developers engaged in the development of TIL-based therapies.
 An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions in this field, and a schematic world map representation engaged in the development of TIL-based therapies.
 Detailed profiles of therapies being evaluated in clinical stages (phase I/II or above).
 An overview of key therapeutic areas that are being targeted by TIL-based therapies. It also includes an assessment of the opportunity across oncological disease indications.
 An analysis of the partnerships that have been established in the recent past.
 An analysis of investments that have been made into companies which have proprietary TIL-based products / technologies.
 A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies.
 An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.
 A review of the key promotional strategies that have been adopted by developers of marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 Target Indication
 Acute Lymphoblastic Leukemia
 Melanoma
 Others
To request for sample report - https://www.rootsanalysis....

 Key Players

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

The research includes brief profiles, featuring an overview of the company, its financial information (if available), details related to its product(s), highlighting type of therapy and current development status, technology portfolio (if available), recent developments and manufacturing capabilities.
 Cellular Biomedicine Group
 Iovnace Biotherapeutics
 Lytix Biopharma
 Phio Pharmaceuticals

For additional details, please visit
https://www.rootsanalysis.... or email salesrootsanalysis.com

You may also be interested in the following titles:
1. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030
2. CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
4. Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://medium.com/RootsA...
LinkedIn: https://medium.com/RootsA...
Twitter: https://medium.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.